1
|
Dobrovolsky VN, Atiq OT, Heflich RH, Maisha M, McKinzie PB, Pearce MG, Robison TW. Erythrocyte PIG-A mutant frequencies in cancer patients receiving cisplatin. Cancer Med 2024; 13:e6895. [PMID: 38214136 PMCID: PMC10905239 DOI: 10.1002/cam4.6895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 12/04/2023] [Accepted: 12/19/2023] [Indexed: 01/13/2024] Open
Abstract
BACKGROUND Cisplatin is a primary chemotherapy choice for various solid tumors. DNA damage caused by cisplatin results in apoptosis of tumor cells. Cisplatin-induced DNA damage, however, may also result in mutations in normal cells and the initiation of secondary malignancies. In the current study, we have used the erythrocyte PIG-A assay to evaluate mutagenesis in non-tumor hematopoietic tissue of cancer patients receiving cisplatin chemotherapy. METHODS Twenty-one head and neck cancer patients undergoing treatment with cisplatin were monitored for the presence of PIG-A mutant total erythrocytes and the young erythrocytes, reticulocytes (RETs), in peripheral blood for up to five and a half months from the initiation of the anti-neoplastic chemotherapy. RESULTS PIG-A mutant frequency (MF) in RETs increased at least two-fold in 15 patients at some point of the monitoring, while the frequency of total mutant RBCs increased at least two-fold in 6 patients. A general trend for an increase in the frequency of mutant RETs and total mutant RBCs was observed in 19 and 18 patients, respectively. Only in one patient did both RET and total RBC PIG-A MFs did not increase at any time-point over the monitoring period. CONCLUSION Cisplatin chemotherapy induces moderate increases in the frequency of PIG-A mutant erythrocytes in head and neck cancer patients. Mutagenicity measured with the flow cytometric PIG-A assay may serve as a tool for predicting adverse outcomes of genotoxic antineoplastic therapy.
Collapse
Affiliation(s)
- Vasily N. Dobrovolsky
- Division of Genetic and Molecular ToxicologyNational Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)JeffersonArkansasUSA
| | - Omar T. Atiq
- University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer InstituteLittle RockArkansasUSA
| | - Robert H. Heflich
- Division of Genetic and Molecular ToxicologyNational Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)JeffersonArkansasUSA
| | - Mackean Maisha
- Office of Scientific Coordination, NCTR, FDAJeffersonArkansasUSA
| | - Page B. McKinzie
- Division of Genetic and Molecular ToxicologyNational Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)JeffersonArkansasUSA
| | - Mason G. Pearce
- Division of Genetic and Molecular ToxicologyNational Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA)JeffersonArkansasUSA
| | - Timothy W. Robison
- Office of New Drugs, OII, DPTII, Center for Drug Evaluation and Research (CDER), US FDASilver SpringMarylandUSA
| |
Collapse
|
2
|
Platel A, Dusautoir R, Kervoaze G, Dourdin G, Gateau E, Talahari S, Huot L, Simar S, Ollivier A, Laine W, Kluza J, Gosset P, Garçon G, Anthérieu S, Guidice JML, Nesslany F. Comparison of the in vivo genotoxicity of electronic and conventional cigarettes aerosols after subacute, subchronic and chronic exposures. JOURNAL OF HAZARDOUS MATERIALS 2022; 423:127246. [PMID: 34844363 DOI: 10.1016/j.jhazmat.2021.127246] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 09/01/2021] [Accepted: 09/13/2021] [Indexed: 06/13/2023]
Abstract
Tobacco smoking is classified as a human carcinogen. A wide variety of new products, in particular electronic cigarettes (e-cigs), have recently appeared on the market as an alternative to smoking. Although the in vitro toxicity of e-cigs is relatively well known, there is currently a lack of data on their long-term health effects. In this context, the aim of our study was to compare, on a mouse model and using a nose-only exposure system, the in vivo genotoxic and mutagenic potential of e-cig aerosols tested at two power settings (18 W and 30 W) and conventional cigarette (3R4F) smoke. The standard comet assay, micronucleus test and Pig-a gene mutation assay were performed after subacute (4 days), subchronic (3 months) and chronic (6 months) exposure. The generation of oxidative stress was also assessed by measuring the 8-hydroxy-2'-deoxyguanosine and by using the hOGG1-modified comet assay. Our results show that only the high-power e-cig and the 3R4F cigarette induced oxidative DNA damage in the lung and the liver of exposed mice. In return, no significant increase in chromosomal aberrations or gene mutations were noted whatever the type of product. This study demonstrates that e-cigs, at high-power setting, should be considered, contrary to popular belief, as hazardous products in terms of genotoxicity in mouse model.
Collapse
Affiliation(s)
- Anne Platel
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Romain Dusautoir
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Gwenola Kervoaze
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, OpInfIELD, France.
| | - Gonzague Dourdin
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Eulalie Gateau
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Smaïl Talahari
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Ludovic Huot
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Sophie Simar
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Anaïs Ollivier
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, OpInfIELD, France.
| | - William Laine
- UMR 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France.
| | - Jérôme Kluza
- UMR 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France.
| | - Philippe Gosset
- University of Lille, CNRS UMR9017, Inserm U1019, CHRU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, OpInfIELD, France.
| | - Guillaume Garçon
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Sébastien Anthérieu
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Jean-Marc Lo Guidice
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| | - Fabrice Nesslany
- CHU Lille, Institut Pasteur de Lille, ULR 4483-IMPact de l'Environnement Chimique sur la Santé (IMPECS), Univ. Lille, Lille, France.
| |
Collapse
|
3
|
Tu H, Yu C, Tong W, Zhou C, Li R, Huang P, Wang Q, Chang Y. Evaluation of the Liver and Blood Micronucleus, and Comet Assay Endpoints in a 14-Day Repeated Dose Study with Methyl Carbamate and 1, 3-Propane Sultone. Mutagenesis 2021; 36:401-406. [PMID: 34516639 DOI: 10.1093/mutage/geab034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2021] [Accepted: 09/12/2021] [Indexed: 11/12/2022] Open
Abstract
The repeated-dose liver micronucleus (RDLMN) assay is a novel method for detecting genotoxic chemicals. Two carcinogens methyl carbamate (MC) and 1, 3-propane sultone (PS) were evaluated for the liver micronucleus in a 14-day repeated-dose study with Sprague Dawley rats. Additionally, micronucleated reticulocytes (MN-RET) in peripheral blood and DNA damage (alkaline comet assay) in the liver were also assessed in the same animals. Ten groups of 5 male Sprague Dawley rats were treated once daily with MC (300, 600, or 1200 mg/kg/day), PS (37.5, 75, or 150 mg/kg/day), negative control, or 3 positive controls by oral gavage for 15 days. Blood samples were collected at 3 hours after the last administration for determining MN-RET frequencies (%MN-RET), and the livers were sampled for determining the frequency of micronuclei and DNA damage. MC was negative in the comet assay, liver micronucleus assay, and reticulocyte micronucleus assay, while PS was positive in all three assays. These results are consistent with the previous genotoxic findings of MC and PS. Therefore, the liver micronucleus assay can be effectively integrated into repeated dose studies in animals. Moreover, integration of multiple genotoxicity endpoints into one study can reduce the number of animals, boost the experimental efficiency, and provides a comprehensive evaluation of the genotoxic potential of chemicals.
Collapse
Affiliation(s)
- Honggang Tu
- School of Pharmacy, Shanghai Jiao Tong University, China.,Shanghai InnoStar Bio-Tech Co. Ltd/National Shanghai Center for New Drug Safety Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Chunrong Yu
- Shanghai InnoStar Bio-Tech Co. Ltd/National Shanghai Center for New Drug Safety Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Wen Tong
- Shanghai InnoStar Bio-Tech Co. Ltd/National Shanghai Center for New Drug Safety Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Changhui Zhou
- Shanghai InnoStar Bio-Tech Co. Ltd/National Shanghai Center for New Drug Safety Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Ruowan Li
- Shanghai InnoStar Bio-Tech Co. Ltd/National Shanghai Center for New Drug Safety Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Pengcheng Huang
- Shanghai InnoStar Bio-Tech Co. Ltd/National Shanghai Center for New Drug Safety Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Qingli Wang
- Center for Drug Evaluation, National Medical Products Administration (China Food and Drug Administration), Beijing, China
| | - Yan Chang
- Shanghai InnoStar Bio-Tech Co. Ltd/National Shanghai Center for New Drug Safety Evaluation and Research, China State Institute of Pharmaceutical Industry, Shanghai, China
| |
Collapse
|
4
|
Revollo JR, McKinzie PB, Robison TW, Dobrovolsky VN. Mutational signatures in T-lymphocytes of rats treated with N-propyl-N-nitrosourea and procarbazine. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2021; 62:350-363. [PMID: 34117657 DOI: 10.1002/em.22448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 05/12/2021] [Accepted: 06/09/2021] [Indexed: 06/12/2023]
Abstract
We have used whole genome sequencing (WGS) to determine mutational signatures induced in the T-cells of rats treated in vivo with N-propyl-N-nitrosourea (PNU) or procarbazine (PCZ). The signatures from the treated rats were different from the signature of background mutations. The main component of the spontaneous T-cell mutational signature was C➔T transition with all other single base substitutions evenly distributed. The PNU-induced mutational signature showed relatively equal contributions from C➔T and T➔C transitions, and T➔A transversions. The PCZ-induced signature was characterized by T➔C transitions, T➔A and, to a smaller extent, T➔G transversions. C➔G transversions were infrequent in either the PNU or PCZ signatures. WGS not only allowed mutational signature detection, but also measured quantitative responses to mutagen treatment: 10-40× increases in the number of mutations per clone were detected in T-cell clones from treated rats. The overall strand specificity of induced mutations for annotated rat genes was comparable to the strand specificity of mutations determined previously for the endogenous X-linked Pig-a gene. Our results provide valuable reference data for future applications of WGS in safety research and risk assessment.
Collapse
Affiliation(s)
- Javier R Revollo
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas, USA
| | - Page B McKinzie
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas, USA
| | - Timothy W Robison
- Division of Pulmonary, Allergy and Critical Care Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
| | - Vasily N Dobrovolsky
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas, USA
| |
Collapse
|
5
|
Revollo JR, Dad A, Pearce MG, Mittelstaedt RA, Casildo A, Lapidus RG, Robison TW, Dobrovolsky VN. CD59-deficient bone marrow erythroid cells from rats treated with procarbazine and propyl-nitrosourea have mutations in the Pig-a gene. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2020; 61:797-806. [PMID: 32729949 DOI: 10.1002/em.22402] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 07/09/2020] [Accepted: 07/24/2020] [Indexed: 06/11/2023]
Abstract
Procarbazine (PCZ) and N-propyl-N-nitrosourea (PNU) are rodent mutagens and carcinogens. Both induce GPI-anchored marker-deficient mutant-phenotype red blood cells (RBCs) in the flow cytometry-based rat RBC Pig-a assay. In the present study, we traced the origin of the RBC mutant phenotype by analyzing Pig-a mutations in the precursors of RBCs, bone marrow erythroid cells (BMEs). Rats were exposed to a total of 450 mg/kg PCZ hydrochloride or 300 mg/kg PNU, and bone marrow was collected 2, 7, and 10 weeks later. Using a flow cell sorter, we isolated CD59-deficient mutant-phenotype BMEs from PCZ- and PNU-treated rats and examined their endogenous X-linked Pig-a gene by next generation sequencing. Pig-a mutations consistent with the properties of PCZ and PNU were found in sorted mutant-phenotype BMEs. PCZ induced mainly A > T transversions with the mutated A on the nontranscribed strand of the Pig-a gene, while PNU induced mainly T > A transversions with the mutated T on the nontranscribed strand. The treatment-induced mutations were distributed across the protein coding sequence of the Pig-a gene. The causal relationship between BMEs and RBCs and the agent-specific mutational spectra in CD59-deicient BMEs indicate that the rat RBC Pig-a assay, scoring CD59-deficient mutant-phenotype RBCs in peripheral blood, detects Pig-a gene mutation.
Collapse
Affiliation(s)
- Javier R Revollo
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA
| | - Azra Dad
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA
| | - Mason G Pearce
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA
| | - Roberta A Mittelstaedt
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA
| | - Andrea Casildo
- Greenbaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - Rena G Lapidus
- Greenbaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - Timothy W Robison
- Division of Pulmonary, Allergy and Critical Care Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Vasily N Dobrovolsky
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA
| |
Collapse
|
6
|
Dertinger SD, Avlasevich SL, Torous DK, Bemis JC, Hove TT, O'Connell O, Martus H, Elhajouji A. Intra- and inter-laboratory reproducibility of the rat blood Pig-a gene mutation assay. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2020; 61:500-507. [PMID: 32187725 DOI: 10.1002/em.22367] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 02/24/2020] [Accepted: 03/13/2020] [Indexed: 06/10/2023]
Abstract
The in vivo Pig-a assay is being used in safety studies to evaluate the potential of chemicals to induce somatic cell gene mutations. Ongoing work is aimed at developing an Organization for Economic Cooperation and Development (OECD) test guideline to support routine use for regulatory purposes (OECD project number 4.93). Among the requirements for OECD approval are demonstrations of assay reliability, including reproducibility within and among laboratories. Experiments reported herein address the reproducibility of the rat blood Pig-a assay using the reference mutagens chlorambucil and melphalan. These agents were evaluated for their ability to induce Pig-a mutant erythrocytes in three separate studies conducted across two laboratories. Each of the studies utilized a common treatment schedule: 28 consecutive days of exposure via oral gavage. Whereas one laboratory studied Crl:CD(SD) rats, the other laboratory used Wistar Han rats. One or two days after cessation of treatment blood samples were collected for mutant reticulocyte and mutant erythrocyte measurements that were accomplished with the same analytical technique whereby samples were depleted of wildtype erythrocytes via immunomagnetic separation followed by flow cytometric enumeration of mutant phenotype cells (MutaFlow®). Dunnett's test results showed similar qualitative outcomes within and between laboratories, that is, each chemical and each study demonstrated statistically significant, dose-related increases in mutant reticulocyte and erythrocyte frequencies. Benchmark dose analysis (PROAST software) provided a means to quantitatively analyze the results, and the relatively tight, overlapping benchmark dose confidence intervals observed for each of the two chemicals indicate that within and between laboratory reproducibility of the Pig-a assay are high, adding further support for the development of an OECD test guideline.
Collapse
Affiliation(s)
| | | | | | | | - Tamsanqa Tafara Hove
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Oliver O'Connell
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Hansjoerg Martus
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| | - Azeddine Elhajouji
- Preclinical Safety, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
| |
Collapse
|